JP2022537555A - ウイルスベースの遺伝子療法による治療方法 - Google Patents

ウイルスベースの遺伝子療法による治療方法 Download PDF

Info

Publication number
JP2022537555A
JP2022537555A JP2021575397A JP2021575397A JP2022537555A JP 2022537555 A JP2022537555 A JP 2022537555A JP 2021575397 A JP2021575397 A JP 2021575397A JP 2021575397 A JP2021575397 A JP 2021575397A JP 2022537555 A JP2022537555 A JP 2022537555A
Authority
JP
Japan
Prior art keywords
patient
gene therapy
viral
smrt
ncor2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021575397A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022537555A5 (cg-RX-API-DMAC7.html
Inventor
イヴァン ビリク
バージット ライペルト
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of JP2022537555A publication Critical patent/JP2022537555A/ja
Publication of JP2022537555A5 publication Critical patent/JP2022537555A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2021575397A 2019-06-20 2020-06-19 ウイルスベースの遺伝子療法による治療方法 Pending JP2022537555A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962864404P 2019-06-20 2019-06-20
US62/864,404 2019-06-20
US201962867172P 2019-06-26 2019-06-26
US62/867,172 2019-06-26
PCT/US2020/038643 WO2020257586A2 (en) 2019-06-20 2020-06-19 Method of treatment with viral-based gene therapy

Publications (2)

Publication Number Publication Date
JP2022537555A true JP2022537555A (ja) 2022-08-26
JP2022537555A5 JP2022537555A5 (cg-RX-API-DMAC7.html) 2023-06-23

Family

ID=71579659

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021575397A Pending JP2022537555A (ja) 2019-06-20 2020-06-19 ウイルスベースの遺伝子療法による治療方法

Country Status (5)

Country Link
US (1) US20200405883A1 (cg-RX-API-DMAC7.html)
EP (1) EP3986481A2 (cg-RX-API-DMAC7.html)
JP (1) JP2022537555A (cg-RX-API-DMAC7.html)
CN (1) CN114375205A (cg-RX-API-DMAC7.html)
WO (1) WO2020257586A2 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114277057B (zh) * 2021-07-09 2023-10-13 上海天泽云泰生物医药有限公司 用于治疗或预防b型血友病的重组腺相关病毒载体和方法
CN115772214B (zh) * 2022-11-30 2023-09-29 湖南家辉生物技术有限公司 F8突变体蛋白、f8基因突变体、检测f8基因突变体的引物组合、试剂及应用
TW202444398A (zh) * 2023-01-09 2024-11-16 美商拜奧馬林製藥公司 表觀遺傳修飾劑改善aav基因療法之耐久性

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017531652A (ja) * 2014-10-06 2017-10-26 アルスロジェン ビー.ブイ.Arthrogen B.V. Aavに基づく遺伝子治療

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU668349B2 (en) 1991-04-25 1996-05-02 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin 6 receptor
US5831005A (en) 1992-09-24 1998-11-03 Chiron Corporation Synthesis of N-substituted oligomers
US5877278A (en) 1992-09-24 1999-03-02 Chiron Corporation Synthesis of N-substituted oligomers
US6458563B1 (en) 1996-06-26 2002-10-01 Emory University Modified factor VIII
WO1999003496A1 (en) 1997-07-21 1999-01-28 The University Of North Carolina At Chapel Hill Factor ix antihemophilic factor with increased clotting activity
US20020014242A1 (en) * 2000-07-31 2002-02-07 Abraham Scaria Use of rapamycin to inhibit immune response and induce tolerance to gene therapy vector and encoded transgene products
BRPI0214168B8 (pt) 2001-11-14 2021-05-25 Centocor Inc anticorpos anti-il-6, moléculas de ácido nucleico codificando os mesmos, vetores compreendendo as referidas moléculas, composições e formulações compreendendo os referidos anticorpos, bem como métodos de produção dos mesmos
PA8672101A1 (es) 2005-04-29 2006-12-07 Centocor Inc Anticuerpos anti-il-6, composiciones, métodos y usos
CN101346395A (zh) 2005-12-30 2009-01-14 默克专利有限公司 阻止复合有IL-6Rα的IL-6与GP130结合的抗IL-6抗体
ATE537190T1 (de) 2006-06-02 2011-12-15 Regeneron Pharma Hochaffine antikörper gegen den humanen il-6- rezeptor
WO2008019061A2 (en) 2006-08-03 2008-02-14 Vaccinex, Inc. Anti-il-6 monoclonal antibodies and uses thereof
WO2008069942A2 (en) 2006-12-05 2008-06-12 Biogen Idec Ma Inc. Novel methods of enhancing delivery of a gene therapy vector using steroids
JP2011520898A (ja) 2008-05-13 2011-07-21 ノビミューン エスアー 抗il−6/il−6r抗体およびそれらの使用方法
MX2011000071A (es) 2008-07-02 2011-05-03 Emergent Product Dev Seattle Inmunoterapeuticos de interleucina-6 (il6).
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
KR20110094307A (ko) 2008-11-13 2011-08-23 펨타 파마슈티컬스, 인크. 인간화된 항-il-6 항체
WO2010115995A2 (en) 2009-04-10 2010-10-14 Ablynx Nv Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
US20110059080A1 (en) 2009-09-08 2011-03-10 Mark Cornfeld Use of an anti-il6 antibody to decrease hepcidin in cancer patients
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
CN103261222B (zh) 2010-09-10 2017-07-28 医疗免疫有限公司 抗体衍生物
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
CN115094062A (zh) * 2015-04-16 2022-09-23 埃默里大学 用于肝脏中蛋白质表达的重组启动子和载体及其用途
AU2016302768B2 (en) * 2015-07-31 2019-08-22 Medimmune Limited Methods for treating hepcidin-mediated disorders
JP2018535929A (ja) * 2015-09-24 2018-12-06 バイオマリン ファーマシューティカル インコーポレイテッド アデノ随伴ウイルス第viii因子ベクター、関連ウイルス粒子、及びそれらを含む治療的製剤
BR112018008900A8 (pt) 2015-11-03 2019-02-26 Regeneron Pharma composições compreendendo anticorpos para il6r para o tratamento de uveíte e edema macular e métodos de uso das mesmas
CN108884145B (zh) * 2015-11-13 2023-08-22 武田药品工业株式会社 用于血友病a的基因治疗的具有增加的表达的编码重组fviii变体的病毒载体
KR102404550B1 (ko) * 2015-11-13 2022-05-31 다케다 야쿠힌 고교 가부시키가이샤 A형 혈우병의 유전자 요법을 위한 증가된 발현을 갖는 재조합 fviii 변이체를 인코딩하는 바이러스 벡터
WO2018029182A1 (en) 2016-08-08 2018-02-15 Ablynx N.V. Il-6r single variable domain antibodies for treatment of il-6r related diseases
WO2018112237A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with an il-6r inhibitor
JP2020506890A (ja) * 2017-01-07 2020-03-05 セレクタ バイオサイエンシーズ インコーポレーテッドSelecta Biosciences,Inc. 合成ナノキャリアにカップリングした免疫抑制剤のパターン化された投与
JP7630906B2 (ja) * 2017-02-01 2025-02-18 イェール・ユニヴァーシティー 利尿薬耐性の治療
WO2018200951A1 (en) * 2017-04-28 2018-11-01 Tran David T Multi-targeted multi-valent ligand-drug particles for the treatment and prevention of diseases and conditions
TWI753168B (zh) 2017-05-22 2022-01-21 日商武田藥品工業股份有限公司 用於血友病b基因療法之編碼具有增強表現的重組fix變異體之病毒載體
CN111051343B (zh) 2017-09-13 2022-11-22 江苏恒瑞医药股份有限公司 Il-6r抗体、其抗原结合片段及医药用途
CN109867723B (zh) 2017-12-05 2022-06-17 南京金斯瑞生物科技有限公司 抗人il6单克隆抗体及其制备方法和用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017531652A (ja) * 2014-10-06 2017-10-26 アルスロジェン ビー.ブイ.Arthrogen B.V. Aavに基づく遺伝子治療

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KLAUDIA KURANDA ET AL.: ""Exposure to wild-type AAV drives distinct capsid immunity profiles in humans"", JOURNAL OF CLINICAL INVESTIGATION, vol. 128, no. 12, JPN6024027726, 22 October 2018 (2018-10-22), pages 5267 - 5279, ISSN: 0005613709 *
VICTORIA M. VELAZQUEZ ET AL.: ""Effective Depletion of Pre-existing Anti-AAV Antibodies Requires Broad Immune Targeting"", MOLECULAR THERAPY - METHODS & CLINICAL DEVELOPMENT, vol. 4, JPN6024027727, March 2017 (2017-03-01), pages 159 - 168, ISSN: 0005613710 *

Also Published As

Publication number Publication date
EP3986481A2 (en) 2022-04-27
CN114375205A (zh) 2022-04-19
WO2020257586A3 (en) 2021-03-04
US20200405883A1 (en) 2020-12-31
WO2020257586A2 (en) 2020-12-24

Similar Documents

Publication Publication Date Title
Herzog et al. Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapy
JP6462044B2 (ja) 第viii因子療法を受けている個体における第viii因子に対する免疫原性を低下させる方法
KR102766526B1 (ko) 간-특이적 작제물인, 인자 viii 발현 카세트 및 이의 사용 방법
Vercelli et al. Regulation of IgE synthesis in humans: a tale of two signals
JP6831779B2 (ja) 修飾された第ix因子、並びに、細胞、器官及び組織への遺伝子導入のための組成物、方法及び使用
JP6290270B2 (ja) 遺伝子操作した樹状細胞および癌の治療のための使用
US20210261919A1 (en) Methods and compositions for treating cancer
AU2019392915B2 (en) Identification and targeting of tumor promoting carcinoma associated fibroblasts for diagnosis and treatment of cancer and other diseases
AU2017214378A1 (en) Optimized Factor VIII genes
US20200405883A1 (en) Method of treatment with viral-based gene therapy
US20240117364A1 (en) Synthetic immunomodulation with a crispr super-repressor in vivo
US20230133243A1 (en) Conditioning regimens for in vivo gene therapy
US20250242056A1 (en) Methods and compositions for using plasma cell depleting agents and/or b cell depleting agents to suppress host anti-aav antibody response and enable aav transduction and re-dosing
US20230159649A1 (en) Methods and combinations for dual targeting of tnf family members
Nayak et al. Prevention and reversal of antibody responses against factor IX in gene therapy for hemophilia B
CN119095612A (zh) 用于在长期停止gaa酶替代疗法的情况下治疗庞贝病的治疗性腺相关病毒
TW202006141A (zh) 使用編碼具有增加表現的重組fviii變異體之病毒載體的a型血友病之基因療法
US8063022B1 (en) Methods for preventing formation of inhibitory antibodies in the setting of gene therapy
US20240269241A1 (en) Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression
RU2799048C2 (ru) Улучшение клинических параметров посредством экспрессии фактора viii
Byrne The Generation and Characterisation of Novel Mouse Models of Haemophilia A
JP2003146909A (ja) 治療用ポリペプチドに対する免疫寛容の誘導
WO2024238591A2 (en) Methods of treating anti-aav seropositive hemophilia patients
HK40121378A (en) Therapeutic adeno-associated virus for treating pompe disease with long term cessation of gaa enzyme replacement therapy
TW202546235A (zh) 腺相關病毒載體序列

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230615

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230615

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230818

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240716

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240912

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241114

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250120

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250319

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250610